FDA Approves Ocrelizumab for Pediatric Patients With Relapsing-Remitting Multiple Sclerosis

In a significant move for pediatric neurology, the FDA has approved the use of intravenous ocrelizumab (Ocrevus) for the treatment of relapsing-remitting multiple sclerosis (RRMS) in children and adolescents. This approval targets a younger patient population that has historically faced a gap in high-efficacy treatment options.

Expanding Treatment Options for Young Patients

The FDA approval extends the use of ocrelizumab, developed by Genentech, to pediatric patients who are 10 years of age or older and weigh at least 55 pounds. While ocrelizumab was already established as a treatment for adults, this decision expands its reach to children and adolescents battling the relapsing-remitting form of MS.

Prior to this pediatric expansion, ocrelizumab was approved for adults dealing with primary progressive MS as well as relapsing forms of the disease, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

“This approval represents a landmark for children living with MS in the U.S. And their families, which can help close the longstanding gap in high-efficacy treatment options for children aged 10 and older,” said Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development at Genentech. “By bringing a decade of efficacy and safety data to this younger population, Ocrevus may reduce relapses and potentially redefine what’s possible for their future.”

Clinical Evidence: The OPERETTA II Trial

The decision to approve ocrelizumab for pediatric use was supported by data from the OPERETTA II trial. In this study, ocrelizumab was compared against fingolimod (Gilenya, Novartis) to measure its effectiveness in managing RRMS.

The trial results indicated that ocrelizumab provided several key benefits:

• Reduced Brain Lesions: Ocrelizumab demonstrated improved rates in reducing both new or enlarging T2 lesions and gadolinium-enhancing T2 lesions compared to fingolimod.
• Relapse Management: The drug showed noninferiority in the annualized relapse rate when compared to fingolimod.

Safety Considerations and Side Effects

While ocrelizumab offers a high-efficacy path for managing MS, it is associated with several serious adverse events that patients and caregivers should discuss with their healthcare providers. Reported risks include:

• Infusion Reactions: Reactions that occur during the administration of the IV medication.
• Immune System Impact: Risks include infection and decreased immunoglobulins.
• Severe Neurological and Organ Risks: Potential for progressive multifocal leukoencephalopathy (PML), colitis, and liver damage.
• Cancer Risk: The treatment may increase the risk for certain types of cancer.

Key Takeaways for Families

Looking Ahead

The approval of ocrelizumab for pediatric patients marks a shift toward providing high-efficacy therapies earlier in the disease progression. By reducing relapses and limiting the formation of new brain lesions in children and adolescents, clinicians hope to improve long-term outcomes for those diagnosed with MS at a young age.